SCHEMBL2811136

SCHEMBL2811136

CC(=O)N1c2ccccc2C(Nc2ccc(CC=O)cc2)CC1C

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 12/20 0.59
BRD2 P25440 8/20 0.59
BRD3 Q15059 8/20 0.59
GFER P55789 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
CYP3A4 P08684 1/20 0.54
CYP2D6 P10635 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
LMNA P02545 2/20 0.53
HDAC1 Q13547 1/20 0.52
HDAC7 Q8WUI4 1/20 0.52
HDAC6 Q9UBN7 1/20 0.52
HDAC9 Q9UKV0 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL220737 0.89 BRD4 (0.74) BRD4BRD2BRD3GFERNPSR1
SCHEMBL223695 0.88 BRD4 (0.63) BRD4BRD2BRD3GFERNPSR1
SCHEMBL221741 0.88 BRD4 (0.63) BRD4BRD2BRD3GFERNPSR1
SCHEMBL223696 0.88 BRD4 (0.63) BRD4BRD2BRD3GFERNPSR1
SCHEMBL224706 0.87 BRD4 (0.62) BRD4BRD2BRD3GFERNPSR1
SCHEMBL4122671 0.86 BRD4 (0.74) BRD4BRD2BRD3GFERNPSR1
SCHEMBL221987 0.86 BRD4 (0.74) BRD4BRD2BRD3GFERNPSR1
SCHEMBL4129055 0.86 BRD4 (0.74) BRD4BRD2BRD3GFERNPSR1
SCHEMBL5836704 0.86 BRD4 (0.74) BRD4BRD2BRD3GFERNPSR1
SCHEMBL4126285 0.86 BRD4 (0.74) BRD4BRD2BRD3GFERNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120004197-A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT KOWA COMPANY, LTD. (JP) 2012-01-05 US disclosed
US-20100222347-A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA, COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT KOWA COMPANY, LTD. (JP) 2010-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004197-A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT EPOR, HBG1, HBG2 BRD4 861/4885BRD2 1499/4885BRD3 1556/4885
US-20100222347-A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA, COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT EPOR, HBG2, HBG1 BRD4 598/4885BRD2 1003/4885BRD3 845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.